Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study)

Oncologist

Volumn 19, Issue 3, 2014, Pages 291-298

  Bruno Ventre, Marta ^a   Ferreri, Andrés J M ^a   Gospodarowicz, Mary ^b   Govi, Silvia ^a   Messina, Carlo ^a   Porter, David ^c   Radford, John ^d   Heo, Dae Seog ^e   Park, Yeon ^f   Martinelli, Giovanni ^g   Taylor, Emma ^h   Lucraft, Helen ⁱ   Hong, Angela ^j   Scarfò, Lydia ^a   Zucca, Emanuele ^k   Christie, David ^l  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e Seoul National University Hospital   (South Korea)

^f Korea Cancer Center Hospital   (South Korea)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Wesley Research Institute   (Australia)

ⁱ Department of Oncology Northern Centre for Cancer   (United Kingdom)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^l BOND UNIVERSITY   (Australia)

more..

Author keywords

Bone lymphoma; Central nervous system prophylaxis; Diffuse large B cell lymphoma; Osteolymphoma; Radiotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ARTICLE; BONE CANCER; BONE LESION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CANCER STAGING; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896475004     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0249     Document Type: Article

References (32)

1. Fletcher CD. The evolving classification of soft tissue tumours: An update based on the new WHO classification. Histopathology 2006; 48: 3-12.
2. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524.
3. Dubey P, Ha CS, Besa PC et al. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1997; 37: 1087-1093.
4. Heyning FH, Hogendoorn PC, Kramer MH et al. Primary non-Hodgkin's lymphoma of bone: A clinicopathological investigation of 60 cases. Leukemia 1999; 13: 2094-2098.
5. Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 1999; 173: 1691-1697.
6. Pellegrini C, Gandolfi L, Quirini F et al. Primary bone lymphoma: Evaluation of chemoimmunotherapy as front-line treatment in 21 patients. Clin Lymphoma Myeloma Leuk 2011; 11: 321-325.
7. Cai L, Stauder MC, Zhang YJ et al. Early-stage primary bone lymphoma: A retrospective, multicenter Rare CancerNetwork (RCN) Study. Int J Radiat Oncol Biol Phys 2012; 83: 284-291.
8. Ramadan KM, Shenkier T, Sehn LH et al. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: A populationbased study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18: 129-135.
9. Ng AK, Mauch PM. Role of radiation therapy in localized aggressive lymphoma. J Clin Oncol 2007; 25: 757-759.
10. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244.
11. Gutiérrez-García G, Colomo L, Villamor N et al. Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010; 51: 1225-1232.
12. Rieger M, Osterborg A, Pettengell R et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study. Ann Oncol 2011; 22: 664-670.
13. Maruyama D, Watanabe T, Beppu Y et al. Primary bone lymphoma: A new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 2007; 37: 216-223.
14. Rathmell AJ, Gospodarowicz MK, Sutcliffe SB et al. Localised lymphoma of bone: Prognostic factors and treatment recommendations. Br J Cancer 1992; 66: 603-606.
15. Barbieri E, Cammelli S, Mauro F et al. Primary non-Hodgkin's lymphoma of the bone: Treatment and analysis of prognostic factors for stage I and stage II. Int J Radiat Oncol Biol Phys 2004; 59: 760-764.
16. Fidias P, Spiro I, Sobczak ML et al. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 1999; 45: 1213-1218.
17. Lewis VO, Primus G, Anastasi J et al. Oncologic outcomes of primary lymphoma of bone in adults. Clin Orthop Relat Res 2003; 41590-97.
18. Horsman JM, Thomas J, Hough R et al. Primary bone lymphoma: A retrospective analysis. Int J Oncol 2006; 28: 1571-1575.
19. Jawad MU, Schneiderbauer MM, Min ES et al. Primary lymphoma of bone in adult patients. Cancer 2010; 116: 871-879.
20. PfreundschuhM, KuhntE, Trümper Letal. CHOPlike chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013-1022.
21. Beal K, Allen L, Yahalom J. Primary bone lymphoma: Treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106: 2652-2656.
22. Zinzani PL, Carrillo G, Ascani S et al. Primary bone lymphoma: Experience with 52 patients. Haematologica 2003; 88: 280-285.
23. Reyes F, Lepage E, GanemGet al. ACVBPversus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
24. Horning SJ, Weller E, KimKet al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004; 22: 3032-3038.
25. Phan J, MazloomA, Medeiros LJ et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010; 28: 4170-4176.
26. Ferreri AJ, Reni M, Ceresoli GL et al. Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin's lymphoma of bone in adults. Cancer Invest 1998; 16: 554-561.
27. Abramson JS, Hellmann M, Barnes JA et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010; 116: 4283-4290.
28. Tomita N, Yokoyama M, Yamamoto W et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2012; 103: 245-251.
29. Villa D, Connors JM, Shenkier TN et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-1052.
30. Boehme V, Schmitz N, Zeynalova S et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896-3902.
31. Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large Bcell lymphoma: A systematic review and metaanalysis. Leuk Lymphoma 2013 [Epub ahead of print].
32. Guirguis HR, Cheung MC, Mahrous M et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: A single centre experience and review of the literature. Br J Haematol 2012; 159: 39-49.